However, given the dependence of platelet survival on BCL‐XL, the use of SMIs targeting this protein is often associated with the occurrence of on‐target and dose‐limiting thrombocytopenia toxicity.99, 100, 101. Here, BCL2L1 is linked to Thrombocytopenia.